国际口腔医学杂志

国际口腔医学杂志 ›› 2026, Vol. 53 ›› Issue (6): 874-883.doi: 10.7518/gjkq.2026606

• 综述 • 上一篇    下一篇

Zeste同源增强子2参与头颈部鳞状细胞癌发生发展的功能与靶向治疗研究

丁薇(),冯海芬,张一迪,江潞,罗小波()   

  1. 口腔疾病防治全国重点实验室 国家口腔医学中心 口腔疾病国家临床医学研究中心 中国医学科学院口腔黏膜癌变与防治创新单元 四川大学华西口腔医院黏膜病科 成都 610041
  • 收稿日期:2025-04-24 修回日期:2026-01-22 出版日期:2026-11-01 发布日期:2026-10-29
  • 通讯作者: 罗小波
  • 作者简介:丁薇，住院医师，硕士，Email：dw_vivian99@163.com
  • 基金资助:
    国家自然科学基金(82272899)

Functional analysis of enhancer of zeste homolog 2 in the pathogenesis of head and neck squamous cell carcinoma and investigation of the targeted therapeutic value

Wei Ding(),Haifen Feng,Yidi Zhang,Lu Jiang,Xiaobo Luo()   

  1. State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management & Dept. of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2025-04-24 Revised:2026-01-22 Online:2026-11-01 Published:2026-10-29
  • Contact: Xiaobo Luo
  • Supported by:
    National Natural Science Foundation of China(82272899)

RichHTML

2

PDF (PC)

8

摘要：

头颈部鳞状细胞癌（HNSCC）是高发恶性肿瘤，患者预后较差。表观遗传调控可参与调节HNSCC的发生发展。作为多梳抑制复合物2的核心催化亚基，Zeste同源增强子2（EZH2）在HNSCC中高表达，通过多种分子机制调控HNSCC的代谢重编程、生长、侵袭转移、免疫逃逸、化疗耐药等生物学过程，是一个极具潜力的治疗靶点。本综述系统总结EZH2在HNSCC发生发展中的功能，并探讨EZH2特异性抑制剂在HNSCC治疗中的应用进展，以期为改善HNSCC患者预后提供新的理论依据。

关键词: Zeste同源增强子2, 头颈部鳞状细胞癌, 侵袭转移, 免疫逃逸, 代谢重编程, 化疗耐药

Abstract:

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignant cancer globally and is associated with poor clinical outcomes. Epigenetic regulation plays a critical role in modulating the pathogenesis and progression of HNSCC. Enhancer of zeste homolog 2 (EZH2), a core catalytic subunit of the polycomb repressive complex 2 (PRC2), is significantly upregulated in HNSCC and contributes to HNSCC progression by modulating such as me-tabolic reprogramming, growth, proliferation, invasion, metastasis, immune evasion, and chemoresistance. Therefore, EZH2 is considered a highly promising therapeutic target, and several ongoing clinical trials are currently investigating its translational potential. This review comprehensively summarizes the functional roles of EZH2 in HNSCC and explores the therapeutic potential of EZH2-specific inhibitors, aiming to provide novel theoretical insights to improve clinical outcomes of HNSCC patients.

Key words: enhancer of zeste homolog 2, head and neck squamous cell carcinoma, invasion and metastasis, immune evasion, metabolic reprogramming, chemotherapeutic resistance

中图分类号: 

  • R739.8

图 1

EZH2的结构示意图及关键功能A：EZH2的结构域；B：PRC2的结构示意图及EZH2的关键表观遗传调控功能。"

图 2

EZH2在HNSCC发生发展中的生物学功能"

[1] Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma[J]. Nat Rev Dis Primers, 2020, 6(1): 92.
[2] Ruffin AT, Li H, Vujanovic L, et al. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment[J]. Nat Rev Cancer, 2023, 23(3): 173-188.
[3] Mei Z, Huang JW, Qiao B, et al. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma[J]. Int J Oral Sci, 2020, 12: 16.
[4] Kang JJ, Ko A, Kil SH, et al. EGFR pathway targe-ting drugs in head and neck cancer in the era of immunotherapy[J]. Biochim Biophys Acta Rev Cancer, 2023, 1878(1): 188827.
[5] Afshari K, Sohal KS. Potential alternative therapeutic modalities for management head and neck squamous cell carcinoma: a review[J]. Cancer Control, 2023, 30: 10732748231185003.
[6] Ndiaye C, Mena M, Alemany L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis[J]. Lancet Oncol, 2014, 15(12): 1319-1331.
[7] Bajbouj K, Al-Ali A, Ramakrishnan RK, et al. Histone modification in NSCLC: molecular mechani-sms and therapeutic targets[J]. Int J Mol Sci, 2021, 22(21): 11701.
[8] Anwar T, Gonzalez ME, Kleer CG. Noncanonical functions of the polycomb group protein EZH2 in breast cancer[J]. Am J Pathol, 2021, 191(5): 774-783.
[9] Wang J, Wang GG. No easy way out for EZH2: its pleiotropic, noncanonical effects on gene regulation and cellular function[J]. Int J Mol Sci, 2020, 21(24): 9501.
[10] Duan R, Du WF, Guo WJ. EZH2: a novel target for cancer treatment[J]. J Hematol Oncol, 2020, 13: 104.
[11] Dasari S, Njiki S, Mbemi A, et al. Pharmacological effects of cisplatin combination with natural pro-ducts in cancer chemotherapy[J]. Int J Mol Sci, 2022, 23(3): 1532.
[12] Xu X, Chen J, Li Y, et al. Targeting epigenetic mo-dulation of cholesterol synthesis as a therapeutic strategy for head and neck squamous cell carcinoma[J]. Cell Death Dis, 2021, 12(5): 482.
[13] Cheng YX, Song ZZ, Fang XD, et al. Polycomb repressive complex 2 and its core component EZH2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma[J]. Clin Epigenetics, 2024, 16: 54.
[14] Bazard P, Pineros J, Acosta AA, et al. Post-translational modifications and age-related hearing loss[J]. Hear Res, 2022, 426: 108625.
[15] Guo YR, Zhao S, Wang GG. Polycomb gene silen-cing mechanisms: PRC2 chromatin targeting, H3K-27me3 ‘readout’, and phase separation-based compaction[J]. Trends Genet, 2021, 37(6): 547-565.
[16] Li MJ, Liu DH, Xue FM, et al. Stage-specific dual function: EZH2 regulates human erythropoiesis by eliciting histone and non-histone methylation[J]. Haematol, 2023, 108(9): 2487-2502.
[17] Sbirkov Y, Schenk T, Kwok C, et al. Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells[J]. Front Cell Dev Biol, 2023, 11: 1076458.
[18] Iragavarapu AG, Yao LQ, Kasinath V. Structural insights into the interactions of Polycomb Repressive Complex 2 with chromatin[J]. Biochem Soc Trans, 2021, 49(6): 2639-2653.
[19] Liu X. A structural perspective on gene repression by polycomb repressive complex 2[M]//Subcellular biochemistry. Cham: Springer International Publi-shing, 2020: 519-562.
[20] Lin XC, Leicher R, Liu SX, et al. Cooperative DNA looping by PRC2 complexes[J]. Nucleic Acids Res, 2021, 49(11): 6238-6248.
[21] Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells[J]. Proc Natl Acad Sci U S A, 2003, 100(20): 11606-11611.
[22] Yang YA, Yu J. EZH2, an epigenetic driver of prostate cancer[J]. Protein Cell, 2013, 4(5): 331-341.
[23] Eich ML, Athar M, Ⅲ Ferguson JE, et al. EZH2-targeted therapies in cancer: hype or a reality[J]. Cancer Res, 2020, 80(24): 5449-5458.
[24] Tai Y, Ji YZ, Liu F, et al. Long noncoding RNA SO-X2-OT facilitates laryngeal squamous cell carcinoma development by epigenetically inhibiting PTEN via methyltransferase EZH2[J]. IUBMB Life, 2019, 71(9): 1230-1239.
[25] Kim KH, Kim L, Choi SJ, et al. The clinicopatholo-gical significance of epithelial mesenchymal transition associated protein expression in head and neck squamous cell carcinoma[J]. Korean J Pathol, 2014, 48(4): 263-269.
[26] Wu ZH, Tang Y, Cheng Q. Data mining identifies six proteins that can act as prognostic markers for head and neck squamous cell carcinoma[J]. Cell Transplant, 2020, 29: 963689720929308.
[27] Cao W, Younis RH, Li J, et al. EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia[J]. Cancer Prev Res, 2011, 4(11): 1816-1824.
[28] Li ZW, Wang YL, Qiu J, et al. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer[J]. Oncotarget, 2013, 4(12): 2532-2549.
[29] Xiao D, Cui XY, Wang X. Long noncoding RNA XI-ST increases the aggressiveness of laryngeal squamous cell carcinoma by regulating miR-124-3p/EZ-H2[J]. Exp Cell Res, 2019, 381(2): 172-178.
[30] Tang Q, Cheng B, Xie M, et al. Circadian clock gene Bmal1 inhibits tumorigenesis and increases paclitaxel sensitivity in tongue squamous cell carcinoma[J]. Cancer Res, 2017, 77(2): 532-544.
[31] Viré E, Brenner C, Deplus R, et al. The polycomb group protein EZH2 directly controls DNA methylation[J]. Nature, 2006, 439(7078): 871-874.
[32] Mochizuki D, Misawa Y, Kawasaki H, et al. Aberrant epigenetic regulation in head and neck cancer due to distinct EZH2 overexpression and DNA hypermethylation[J]. Int J Mol Sci, 2018, 19(12): 3707.
[33] Nong SQ, Han XY, Xiang Y, et al. Metabolic reprogramming in cancer: mechanisms and therapeutics[J]. MedComm, 2023, 4(2): e218.
[34] Sun S, Wu Y, Guo W, et al. STAT3/HOTAIR signa-ling axis regulates HNSCC growth in an EZH2-dependent manner[J]. Clin Cancer Res, 2018, 24(11): 2665-2677.
[35] Cheng Y, Chen J, Shi Y, et al. MAPK signaling pa-thway in oral squamous cell carcinoma: biological function and targeted therapy[J]. Cancers (Basel), 2022, 14(19): 4625.
[36] Chen JH, Tang SS, Zheng QH, et al. The competitive mechanism of EZH1 and EZH2 in promoting oral squamous cell carcinoma[J]. Exp Cell Res, 2024, 436(1): 113957.
[37] Chang JW, Gwak SY, Shim GA, et al. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity[J]. Oral Oncol, 2016, 52: 66-74.
[38] Luo HN, Jiang Y, Ma SJ, et al. EZH2 promotes in-vasion and metastasis of laryngeal squamous cells carcinoma via epithelial-mesenchymal transition through H3K27me3[J]. Biochem Biophys Res Commun, 2016, 479(2): 253-259.
[39] Zhao MH, Hu XM, Xu YN, et al. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regula-ting the STAT3/VEGFR2 axis[J]. Int J Oncol, 2019, 55(5): 1165-1175.
[40] Tong ZT, Cai MY, Wang XG, et al. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDA-C2 and Snail to inhibit E-cadherin[J]. Oncogene, 2012, 31(5): 583-594.
[41] Zheng M, Cao MX, Luo XJ, et al. EZH2 promotes invasion and tumour glycolysis by regulating STA-T3 and FoxO1 signalling in human OSCC cells[J]. J Cell Mol Med, 2019, 23(10): 6942-6954.
[42] Zheng M, Jiang YP, Chen W, et al. Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma[J]. Oncotarget, 2015, 6(9): 6794-6810.
[43] Liu XQ, Wang C, Chen ZJ, et al. MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines[J]. Biochem J, 2011, 440(1): 23-31.
[44] Li YR, Wan Q, Wang WW, et al. LncRNA ADAMTS9-AS2 promotes tongue squamous cell carcinoma proliferation, migration and EMT via the miR-600/EZH2 axis[J]. Biomed Pharmacother, 2019, 112: 108719.
[45] Wu YS, Zhang L, Wang Y, et al. Long noncoding RNA HOTAIR involvement in cancer[J]. Tumor Biol, 2014, 35(10): 9531-9538.
[46] Zhou X, Ren Y, Kong LP, et al. Targeting EZH2 regulates tumor growth and apoptosis through mo-dulating mitochondria dependent cell-death pathway in HNSCC[J]. Oncotarget, 2015, 6(32): 33720-33732.
[47] Kong L, Zhou X, Wu Y, et al. Targeting HOTAIR induces mitochondria related apoptosis and inhibits tumor growth in head and neck squamous cell carcinoma in vitro and in vivo [J]. Curr Mol Med, 2015, 15(10): 952-960.
[48] Duan YS, Yue K, Ye BB, et al. LncRNA MALA-T1 promotes growth and metastasis of head and neck squamous cell carcinoma by repressing VHL through a non-canonical function of EZH2[J]. Cell Death Dis, 2023,14(2): 149.
[49] Chen W, Wang HT, Ji JF, et al. Epigenetic network of EZH2/SFRP1/Wnt in the epithelial-mesenchymal transition of laryngeal carcinoma cells[J]. Neoplasma, 2022, 69(3): 680-690.
[50] Rana PS, Ignatz-Hoover JJ, Driscoll JJ. Targeting proteasomes and the MHC classⅠantigen presentation machinery to treat cancer, infections and age-related diseases[J]. Cancers, 2023, 15(23): 5632.
[51] Zhou L, Mudianto T, Ma X, et al. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer[J]. Clin Cancer Res, 2020, 26(1): 290-300.
[52] Li YL, Goldberg EM, Chen X, et al. Histone methy-lation antagonism drives tumor immune evasion in squamous cell carcinomas[J]. Mol Cell, 2022, 82(20): 3901-3918.e7.
[53] Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing mye-loid cell diversity[J]. Nat Rev Immunol, 2021, 21(8): 485-498.
[54] Liu J, Lin WP, Su W, et al. Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC[J]. Int Immunopharmacol, 2023, 119: 110243.
[55] Pandruvada S, Kessler R, Thai A. Head and neck cancer treatment in the era of molecular medicine[J]. Adv Cancer Res, 2023, 160: 205-252.
[56] Samaržija I, Tomljanović M, Novak Kujundžić R, et al. EZH2 inhibition and cisplatin as a combination anticancer therapy: an overview of preclinical stu-dies[J]. Cancers, 2022, 14(19): 4761.
[57] Chen Y, Zhu HY, Luo Y, et al. EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancer[J]. Biomed Pharmacother, 2024, 175: 116624.
[58] Huang YP, Kesselman D, Kizub D, et al. Phospho-ΔNp63α/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure[J]. Cell Cycle, 2013, 12(4): 684-697.
[59] Huang YX, Wang XY, Niu XS, et al. EZH2 suppresses the nucleotide excision repair in nasopharyngeal carcinoma by silencing XPA gene[J]. Mol Carcinog, 2017, 56(2): 447-463.
[60] Brkic FF, Stoiber S, Maier T, et al. Targeting wnt/beta-catenin signaling in HPV-positive head and neck squamous cell carcinoma[J]. Pharmaceuticals, 2022, 15(3): 378.
[61] Milan TM, Eskenazi APE, de Oliveira LD, et al. Interplay between EZH2/β-catenin in stemness of cisplatin-resistant HNSCC and their role as therapeutic targets[J]. Cell Signal, 2023, 109: 110773.
[62] Jin X, Kim LJY, Wu QL, et al. Targeting glioma stem cells through combined BMI1 and EZH2 inhibition[J]. Nat Med, 2017, 23(11): 1352-1361.
[63] Roy S, Kar M, Roy S, et al. Inhibition of CD44 sensitizes cisplatin-resistance and affects Wnt/β-catenin signaling in HNSCC cells[J]. Int J Biol Macromol, 2020, 149: 501-512.
[64] Reppel L, Tsahouridis O, Akulian J, et al. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer[J]. J Immuno-ther Cancer, 2022, 10(1): e003897.
[65] Gannon OM, Merida de Long L, Endo-Munoz L, et al. Dysregulation of the repressive H3K27 trimethy-lation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differen-tiation[J]. Clin Cancer Res, 2013, 19(2): 428-441.
[66] Idris S, Lindsay C, Kostiuk M, et al. Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer[J]. J Otolaryngol Head Neck Surg, 2016, 45: 54.
[67] Grover A, Sanseviero E, Timosenko E, et al. Myeloid-derived suppressor cells: a propitious road to clinic[J]. Cancer Discov, 2021, 11(11): 2693-2706.
[68] Romanelli A, Stazi G, Fioravanti R, et al. Design of first-in-class dual EZH2/HDAC inhibitor: biochemical activity and biological evaluation in cancer cells[J]. ACS Med Chem Lett, 2020, 11(5): 977-983.
[69] Zhang L, Li HT, Shereda R, et al. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma[J]. Cancer Lett, 2022, 548: 215899.
[70] Lei C, Li S, Fan Y, et al. LncRNA DUXAP8 indu-ces breast cancer radioresistance by modulating the PI3K/AKT/mTOR pathway and the EZH2-E-cadherin/RHOB pathway[J]. Cancer Biol Ther, 2022, 23(1): 1-13.
[71] Yap TA, Winter JN, Giulino-Roth L, et al. Phase Ⅰ study of the novel enhancer of zeste homolog 2 (EZ-H2) inhibitor GSK2816126 in patients with advan-ced hematologic and solid tumors[J]. Clin Cancer Res, 2019, 25(24): 7331-7339.
[72] Kaundal B, Srivastava AK, Dev A, et al. Nanoformulation of EPZ011989 attenuates EZH2-c-Myb epigenetic interaction by proteasomal degradation in acute myeloid leukemia[J]. Mol Pharm, 2020, 17(2): 604-621.
[1] 刘明,周妍亭,李敬. β-1,4-N-乙酰半乳糖胺基转移酶4在头颈部鳞状细胞癌中的表达规律及功能初探[J]. 国际口腔医学杂志, 2026, 53(2): 189-196.
[2] 武旭,达林泰,苏尼特,尚多,周兴安,德乐黑巴特尔. CXCL趋化因子在头颈部鳞状细胞癌中的表达及临床意义[J]. 国际口腔医学杂志, 2024, 51(3): 303-309.
[3] 王苗,孟婉蓉,李龙江. 基于胱氨酸-谷氨酸反向转运体的抗肿瘤代谢治疗新策略[J]. 国际口腔医学杂志, 2024, 51(1): 10-20.
[4] 刘世一, 陈中, 张素欣. 程序性死亡受体/配体免疫治疗策略在人乳头瘤病毒阳性头颈部鳞状细胞癌中的研究进展[J]. 国际口腔医学杂志, 2024, 51(1): 21-27.
[5] 李奕君, 徐子昂, 李一. 前哨淋巴结在头颈部鳞状细胞癌检测的应用进展[J]. 国际口腔医学杂志, 2023, 50(5): 521-527.
[6] 徐智博,孟秀萍. 粪肠球菌逃逸宿主免疫防御机制的研究进展[J]. 国际口腔医学杂志, 2023, 50(5): 613-617.
[7] 李洪芳,陈中,张素欣. 免疫检查点抑制剂联合放射治疗在头颈部鳞状细胞癌治疗中的研究进展[J]. 国际口腔医学杂志, 2022, 49(5): 614-620.
[8] 郝福,孙睿. 头颈部鳞状细胞癌第二原发癌的研究进展[J]. 国际口腔医学杂志, 2019, 46(5): 585-592.
[9] 毛璐,鞠侯雨,任国欣. 程序性细胞死亡受体-1与其配体信号通路的调控及其在头颈鳞状细胞癌治疗中的研究进展[J]. 国际口腔医学杂志, 2018, 45(5): 560-565.
[10] 李格格, 潘佳慧, 唐秋玲, 刘歆婵, 侯玉帛, 于维先. 牙龈素促进牙龈卟啉单胞菌免疫逃逸的机制[J]. 国际口腔医学杂志, 2017, 44(5): 519-522.
[11] 桑磊1，2 李宏卫2，3. 口腔鳞状细胞癌治疗特异性靶点整联蛋白-αvsub>β6sub>的研究进展[J]. 国际口腔医学杂志, 2013, 40(1): 72-75.
[12] 李金,廖贵清,. TEXs在肿瘤免疫中的研究进展[J]. 国际口腔医学杂志, 2006, 33(06): 451-453.
[13] 黄静,陈新明. 单核苷酸多态与头颈部鳞状细胞癌发生风险的研究进展[J]. 国际口腔医学杂志, 2005, 32(04): 269-271.
[14] 王志国,褚存超,郭伟. 比较基因组杂交技术在头颈部鳞癌诊断中的研究进展[J]. 国际口腔医学杂志, 2004, 31(05): 365-367.
[15] 薛凡 张引成. IgSF类细胞粘附分子在头颈部肿瘤侵袭转移作用中的研究进展[J]. 国际口腔医学杂志, 2003, 30(06): 444-446.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!